JP2019511491A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019511491A5 JP2019511491A5 JP2018547320A JP2018547320A JP2019511491A5 JP 2019511491 A5 JP2019511491 A5 JP 2019511491A5 JP 2018547320 A JP2018547320 A JP 2018547320A JP 2018547320 A JP2018547320 A JP 2018547320A JP 2019511491 A5 JP2019511491 A5 JP 2019511491A5
- Authority
- JP
- Japan
- Prior art keywords
- expression
- targeting ligand
- oligomeric compound
- pharmaceutically acceptable
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021189879A JP7485642B2 (ja) | 2016-03-07 | 2021-11-24 | 治療化合物用の標的化リガンド |
| JP2024074913A JP2024097862A (ja) | 2016-03-07 | 2024-05-02 | 治療化合物用の標的化リガンド |
| JP2025092644A JP2025120251A (ja) | 2016-03-07 | 2025-06-03 | 治療化合物用の標的化リガンド |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662304652P | 2016-03-07 | 2016-03-07 | |
| US62/304,652 | 2016-03-07 | ||
| US201662370754P | 2016-08-04 | 2016-08-04 | |
| US62/370,754 | 2016-08-04 | ||
| US201662426916P | 2016-11-28 | 2016-11-28 | |
| US62/426,916 | 2016-11-28 | ||
| PCT/US2017/021175 WO2017156012A1 (en) | 2016-03-07 | 2017-03-07 | Targeting ligands for therapeutic compounds |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021189879A Division JP7485642B2 (ja) | 2016-03-07 | 2021-11-24 | 治療化合物用の標的化リガンド |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019511491A JP2019511491A (ja) | 2019-04-25 |
| JP2019511491A5 true JP2019511491A5 (https=) | 2020-04-16 |
| JP6983797B2 JP6983797B2 (ja) | 2021-12-17 |
Family
ID=59723428
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018547320A Active JP6983797B2 (ja) | 2016-03-07 | 2017-03-07 | 治療化合物用の標的化リガンド |
| JP2021189879A Active JP7485642B2 (ja) | 2016-03-07 | 2021-11-24 | 治療化合物用の標的化リガンド |
| JP2024074913A Withdrawn JP2024097862A (ja) | 2016-03-07 | 2024-05-02 | 治療化合物用の標的化リガンド |
| JP2025092644A Pending JP2025120251A (ja) | 2016-03-07 | 2025-06-03 | 治療化合物用の標的化リガンド |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021189879A Active JP7485642B2 (ja) | 2016-03-07 | 2021-11-24 | 治療化合物用の標的化リガンド |
| JP2024074913A Withdrawn JP2024097862A (ja) | 2016-03-07 | 2024-05-02 | 治療化合物用の標的化リガンド |
| JP2025092644A Pending JP2025120251A (ja) | 2016-03-07 | 2025-06-03 | 治療化合物用の標的化リガンド |
Country Status (14)
| Country | Link |
|---|---|
| US (4) | US10246709B2 (https=) |
| EP (1) | EP3426261A4 (https=) |
| JP (4) | JP6983797B2 (https=) |
| KR (3) | KR102830443B1 (https=) |
| CN (2) | CN113797348A (https=) |
| AU (3) | AU2017229469B2 (https=) |
| BR (1) | BR112018068230B1 (https=) |
| CA (1) | CA3011946A1 (https=) |
| IL (3) | IL296377A (https=) |
| JO (2) | JOP20170057B1 (https=) |
| MX (3) | MX2018009854A (https=) |
| TW (3) | TWI727009B (https=) |
| UY (1) | UY37146A (https=) |
| WO (1) | WO2017156012A1 (https=) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201620526A (zh) | 2014-06-17 | 2016-06-16 | 愛羅海德研究公司 | 用於抑制α－１抗胰蛋白酶基因表現之組合物及方法 |
| JOP20160211B1 (ar) | 2015-10-01 | 2021-08-17 | Arrowhead Pharmaceuticals Inc | تراكيب وأساليب لتثبيط تعبير جيني للـ lpa |
| CA3011946A1 (en) * | 2016-03-07 | 2017-09-14 | Arrowhead Pharmaceuticals, Inc. | Targeting ligands for therapeutic compounds |
| MX2018015109A (es) | 2016-06-06 | 2019-04-22 | Arrowhead Pharmaceuticals Inc | Nucleotidos modificados con 5'-ciclo-fosfonato. |
| JOP20190015A1 (ar) | 2016-08-04 | 2019-02-04 | Arrowhead Pharmaceuticals Inc | عوامل (ار ان ايه آي) لعدوى فيروس الالتهاب الكبدي الوبائي ب |
| SG11201901841TA (en) | 2016-09-02 | 2019-03-28 | Arrowhead Pharmaceuticals Inc | Targeting ligands |
| CN110268060B (zh) | 2017-01-10 | 2024-07-26 | 箭头药业股份有限公司 | α-1抗胰蛋白酶(AAT)RNAi物质、包含AAT RNAi物质的组合物和使用方法 |
| AU2018213379A1 (en) | 2017-01-30 | 2019-07-18 | Arrowhead Pharmaceuticals Inc. | Compositions and methods for inhibition of factor XII gene expression |
| KR20240161202A (ko) | 2017-09-11 | 2024-11-12 | 애로우헤드 파마슈티컬스 인코포레이티드 | 아포지단백질 C-III (APOC3)의 발현을 억제하기 위한 RNAi 작용제 및 조성물 |
| TN2020000038A1 (en) | 2017-09-14 | 2021-10-04 | Arrowhead Pharmaceuticals Inc | Rnai agents and compositions for inhibiting expression of angiopoietin-like 3 (angptl3), and methods of use |
| JP7473472B2 (ja) | 2017-10-17 | 2024-04-23 | アローヘッド ファーマシューティカルズ インコーポレイテッド | アシアロ糖タンパク質受容体１の発現を阻害するためのＲＮＡｉ剤および組成物 |
| KR102769565B1 (ko) * | 2018-09-19 | 2025-02-20 | 애로우헤드 파마슈티컬스 인코포레이티드 | 17베타-HSD 유형 13- (HSD17B13)의 발현을 억제하기 위한 RNAi 작용제, 그의 조성물, 및 사용 방법 |
| CN111377985B (zh) * | 2018-12-29 | 2023-11-10 | 苏州瑞博生物技术股份有限公司 | 化合物和缀合物及其制备方法和用途 |
| MX2021015003A (es) | 2019-06-06 | 2022-01-24 | Arrowhead Pharmaceuticals Inc | Metodos para el tratamiento de la deficiencia de alfa-1 antitripsina (aatd). |
| KR20220042116A (ko) | 2019-06-18 | 2022-04-04 | 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 | B형 간염 바이러스(HBV) 백신 및 HBV-타케팅 RNAi의 조합 |
| JP7720788B2 (ja) | 2019-06-25 | 2025-08-08 | アムジエン・インコーポレーテツド | 炭水化物に連結されたオリゴヌクレオチドのための精製方法 |
| JP7672394B2 (ja) | 2019-09-03 | 2025-05-07 | アークトゥラス・セラピューティクス・インコーポレイテッド | 治療的に活性な複合体のアシアロ糖タンパク質受容体媒介送達 |
| GB2613225B (en) * | 2020-03-04 | 2024-01-03 | Verve Therapeutics Inc | Compositions and methods for targeted RNA delivery |
| EP4126967A1 (en) | 2020-03-23 | 2023-02-08 | Amgen Inc. | Monoclonal antibodies to chemically-modified nucleic acids and uses thereof |
| AR121672A1 (es) | 2020-03-26 | 2022-06-29 | Arrowhead Pharmaceuticals Inc | AGENTES DE ARNi PARA INHIBIR LA EXPRESIÓN DE PNPLA3, COMPOSICIONES FARMACÉUTICAS DE ESTA, Y MÉTODOS DE USO |
| WO2021198958A1 (en) | 2020-04-01 | 2021-10-07 | Janssen Biopharma, Inc. | Nucleic acid polymers |
| WO2021206182A1 (ja) * | 2020-04-10 | 2021-10-14 | 学校法人 聖マリアンナ医科大学 | 化合物、造影剤、及び化合物の製造方法 |
| TW202214301A (zh) * | 2020-06-16 | 2022-04-16 | 大陸商上海拓界生物醫藥科技有限公司 | 一種碳水化合物分子簇及其製備方法和醫藥用途 |
| JP7846095B2 (ja) | 2020-09-15 | 2026-04-14 | アローヘッド ファーマシューティカルズ インコーポレイテッド | Ｚ－ａａｔタンパク質のレベルを低下させる方法 |
| AU2021373780A1 (en) | 2020-11-05 | 2023-06-08 | Amgen Inc. | METHODS FOR TREATING ATHEROSCLEROTIC CARDIOVASCULAR DISEASE WITH LPA-TARGETED RNAi CONSTRUCTS |
| IL303886A (en) | 2020-12-23 | 2023-08-01 | Flagship Pioneering Inc | Compositions of modified trems and uses thereof |
| TW202304472A (zh) | 2021-04-23 | 2023-02-01 | 美商格納生物公司 | 經聚醣修飾之核酸、製備方法及治療用途 |
| US11629349B2 (en) | 2021-06-21 | 2023-04-18 | Arrowhead Pharmaceuticals, Inc. | RNAi agents for inhibiting expression of xanthine dehydrogenase (XDH), pharmaceutical compositions thereof, and methods of use |
| CN117377765A (zh) * | 2021-07-02 | 2024-01-09 | 上海拓界生物医药科技有限公司 | 一种核酸配体及其缀合物、其制备方法和用途 |
| WO2023015223A2 (en) | 2021-08-03 | 2023-02-09 | Verve Therapeutics, Inc. | Compositions and methods for targeted rna delivery |
| CN114703184B (zh) * | 2022-03-11 | 2024-06-18 | 厦门甘宝利生物医药有限公司 | Lpa抑制剂及其用途 |
| WO2023196941A1 (en) | 2022-04-08 | 2023-10-12 | Arrowhead Pharmaceuticals, Inc. | Treatment of a non-alcoholic fatty liver disease |
| KR20250006258A (ko) | 2022-05-02 | 2025-01-10 | 암젠 인크 | 탄수화물 표적화 모이어티인 nag-25를 제조하는 프로세스 및 이의 중간체 |
| WO2023233290A1 (en) | 2022-05-31 | 2023-12-07 | Janssen Sciences Ireland Unlimited Company | Rnai agents targeting pd-l1 |
| US20250179492A1 (en) | 2022-06-22 | 2025-06-05 | Flagship Pioneering Innovations Vi, Llc | Compositions of modified trems and uses thereof |
| EP4684015A2 (en) | 2023-03-21 | 2026-01-28 | Arrowhead Pharmaceuticals, Inc. | Rnai agents for inhibiting expression of complement factor b (cfb), pharmaceutical compositions thereof, and methods of use |
| CN121079106A (zh) | 2023-05-31 | 2025-12-05 | 上海拓界生物医药科技有限公司 | 一种靶向LPA的dsRNA及其应用 |
| GB202311334D0 (en) | 2023-07-24 | 2023-09-06 | Astrazeneca Ab | Multivalent cargo-carrying complexes and uses thereof |
| WO2025021831A1 (en) | 2023-07-24 | 2025-01-30 | Astrazeneca Ab | Multivalent cargo-carrying complexes and uses thereof |
| GB202311324D0 (en) | 2023-07-24 | 2023-09-06 | Astrazeneca Ab | Multivalent cargo-carrying complexes and uses thereof |
| WO2025038661A1 (en) | 2023-08-14 | 2025-02-20 | Arrowhead Pharmaceuticals, Inc. | Oligonucleotide synthesis methods |
| WO2025042786A1 (en) | 2023-08-18 | 2025-02-27 | Flagship Pioneering Innovations Vi, Llc | Compositions comprising circular polyribonucleotides and uses thereof |
| IL326882A (en) | 2023-08-30 | 2026-04-01 | Arrowhead Pharmaceuticals Inc | RNAi agents for inhibiting expression of inhibitory subunit beta E (INHBE), their pharmaceutical compositions and methods of use |
| CN121969377A (zh) | 2023-10-06 | 2026-05-01 | 葛兰素史密斯克莱知识产权(第3号)有限公司 | 非酒精性脂肪性肝病的治疗 |
| US20250161347A1 (en) | 2023-11-22 | 2025-05-22 | Flagship Pioneering Innovations Vii, Llc | Methods and compositions for treating non-alcoholic fatty liver disease |
| WO2025226980A2 (en) | 2024-04-25 | 2025-10-30 | Insitro, Inc. | Compositions and methods for treating metabolic dysfunction-associated steatotic liver disease |
| WO2025245188A2 (en) | 2024-05-21 | 2025-11-27 | Flagship Pioneering Innovations Vii, Llc | Methods of treating liver steatosis and non-alcoholic fatty liver disease |
Family Cites Families (97)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4469863A (en) | 1980-11-12 | 1984-09-04 | Ts O Paul O P | Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4751219A (en) | 1985-02-05 | 1988-06-14 | Nederlandse Centrale Organisatie Voor Toegepast-Natuur-Wetenschappelijk Onderzoek | Synthetic glycolipides, a process for the preparation thereof and several uses for these synthetic glycolipides |
| NL9201440A (nl) | 1992-08-11 | 1994-03-01 | Univ Leiden | Triantennaire clusterglycosiden, hun bereiding en toepassing. |
| US6172045B1 (en) | 1994-12-07 | 2001-01-09 | Neorx Corporation | Cluster clearing agents |
| US6908903B1 (en) | 1994-12-07 | 2005-06-21 | Aletheon Pharmaceuticals, Inc. | Cluster clearing agents |
| CN1120707C (zh) | 1995-11-22 | 2003-09-10 | 约翰斯·霍普金斯大学 | 增强生物分子的细胞摄取的配体 |
| US20030119724A1 (en) | 1995-11-22 | 2003-06-26 | Ts`O Paul O.P. | Ligands to enhance cellular uptake of biomolecules |
| US5998203A (en) | 1996-04-16 | 1999-12-07 | Ribozyme Pharmaceuticals, Inc. | Enzymatic nucleic acids containing 5'-and/or 3'-cap structures |
| CN1231675A (zh) | 1996-09-26 | 1999-10-13 | 味之素株式会社 | 修饰的生理活性蛋白及含有该蛋白的药物组合物 |
| US6300319B1 (en) | 1998-06-16 | 2001-10-09 | Isis Pharmaceuticals, Inc. | Targeted oligonucleotide conjugates |
| CN1191093C (zh) * | 1998-10-30 | 2005-03-02 | 第一制药株式会社 | Dds化合物及其测定方法 |
| US6383812B1 (en) | 1999-05-28 | 2002-05-07 | Academia Sinica | Anti liver disease drug R-YEEE and method of synthesizing branched galactose-terminal glycoproteins |
| US20080281041A1 (en) | 1999-06-07 | 2008-11-13 | Rozema David B | Reversibly Masked Polymers |
| US8541548B2 (en) | 1999-06-07 | 2013-09-24 | Arrowhead Madison Inc. | Compounds and methods for reversible modification of biologically active molecules |
| US7491805B2 (en) | 2001-05-18 | 2009-02-17 | Sirna Therapeutics, Inc. | Conjugates and compositions for cellular delivery |
| US7833992B2 (en) | 2001-05-18 | 2010-11-16 | Merck Sharpe & Dohme | Conjugates and compositions for cellular delivery |
| ES2336887T5 (es) | 2000-03-30 | 2019-03-06 | Whitehead Inst Biomedical Res | Mediadores de interferencia por ARN específicos de secuencias de ARN |
| CA2429814C (en) | 2000-12-01 | 2014-02-18 | Thomas Tuschl | Rna interference mediating small rna molecules |
| CN100406065C (zh) | 2000-12-01 | 2008-07-30 | 细胞工厂治疗公司 | 糖基化/半乳糖基化肽、双官能接头和核苷酸单体/多聚体的缀合物以及相关的组合物和使用方法 |
| EP1386004A4 (en) | 2001-04-05 | 2005-02-16 | Ribozyme Pharm Inc | MODULATION OF GENE EXPRESSION ASSOCIATED WITH INFLAMMATORY PROLIFERATION AND GROWTH OF NEURITIES BY METHODS INVOLVING NUCLEIC ACID |
| ATE427948T1 (de) | 2001-04-24 | 2009-04-15 | Purdue Research Foundation | Folat-mimetika und deren folatrezeptorbindende konjugate |
| EP2415486B1 (en) | 2001-05-18 | 2017-02-22 | Sirna Therapeutics, Inc. | Conjugates and compositions for cellular delivery |
| US7109165B2 (en) | 2001-05-18 | 2006-09-19 | Sirna Therapeutics, Inc. | Conjugates and compositions for cellular delivery |
| WO2003008628A2 (en) | 2001-07-20 | 2003-01-30 | Ribozyme Pharmacuticals, Inc. | Enzymatic nucleic acid peptide conjugates |
| US7439043B2 (en) | 2001-10-10 | 2008-10-21 | Neose Technologies, Inc. | Galactosyl nucleotide sugars |
| US20100240730A1 (en) | 2002-02-20 | 2010-09-23 | Merck Sharp And Dohme Corp. | RNA Interference Mediated Inhibition of Gene Expression Using Chemically Modified Short Interfering Nucleic Acid (siNA) |
| CA2498772A1 (en) | 2002-09-11 | 2004-03-25 | Santaris Pharma A/S | Modified pna molecules |
| WO2004090108A2 (en) | 2003-04-03 | 2004-10-21 | Alnylam Pharmaceuticals | Irna conjugates |
| CA2518475C (en) | 2003-03-07 | 2014-12-23 | Alnylam Pharmaceuticals, Inc. | Irna agents comprising asymmetrical modifications |
| US7851615B2 (en) | 2003-04-17 | 2010-12-14 | Alnylam Pharmaceuticals, Inc. | Lipophilic conjugated iRNA agents |
| ES2702942T3 (es) | 2003-04-17 | 2019-03-06 | Alnylam Pharmaceuticals Inc | Agentes de ARNi modificados |
| US7723509B2 (en) | 2003-04-17 | 2010-05-25 | Alnylam Pharmaceuticals | IRNA agents with biocleavable tethers |
| WO2004101619A1 (ja) | 2003-05-15 | 2004-11-25 | Shionogi Co., Ltd. | 機能的糖ペプチドの合理的設計および合成 |
| EP1791567B1 (en) | 2004-08-10 | 2015-07-29 | Alnylam Pharmaceuticals Inc. | Chemically modified oligonucleotides |
| US20090203132A1 (en) | 2004-09-09 | 2009-08-13 | Swayze Eric E | Pyrrolidinyl groups for attaching conjugates to oligomeric compounds |
| US20060148740A1 (en) | 2005-01-05 | 2006-07-06 | Prosensa B.V. | Mannose-6-phosphate receptor mediated gene transfer into muscle cells |
| US20080206869A1 (en) | 2005-01-24 | 2008-08-28 | Avaris Ab | Nucleic Acid Complex |
| US8658211B2 (en) | 2006-08-18 | 2014-02-25 | Arrowhead Madison Inc. | Polyconjugates for in vivo delivery of polynucleotides |
| CN101500548A (zh) | 2006-08-18 | 2009-08-05 | 弗·哈夫曼-拉罗切有限公司 | 用于体内递送多核苷酸的多缀合物 |
| US9216228B2 (en) | 2007-02-16 | 2015-12-22 | KTB Tumorforschungsgesellschaft MBM | Receptor and antigen targeted prodrug |
| CA2685127C (en) | 2007-04-23 | 2019-01-08 | Alnylam Pharmaceuticals, Inc. | Glycoconjugates of rna interference agents |
| WO2009082606A2 (en) | 2007-12-04 | 2009-07-02 | Alnylam Pharmaceuticals, Inc. | Folate conjugates |
| WO2009073809A2 (en) | 2007-12-04 | 2009-06-11 | Alnylam Pharmaceuticals, Inc. | Carbohydrate conjugates as delivery agents for oligonucleotides |
| CA2713379A1 (en) | 2008-01-31 | 2009-11-05 | Alnylam Pharmaceuticals, Inc. | Optimized methods for delivery of dsrna targeting the pcsk9 gene |
| US20110130440A1 (en) | 2008-03-26 | 2011-06-02 | Alnylam Pharmaceuticals, Inc. | Non-natural ribonucleotides, and methods of use thereof |
| CA2721183C (en) | 2008-04-11 | 2019-07-16 | Alnylam Pharmaceuticals, Inc. | Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components |
| AU2009298802A1 (en) | 2008-09-23 | 2010-04-08 | Alnylam Pharmaceuticals, Inc. | Chemical modifications of monomers and oligonucleotides with cycloaddition |
| MX360460B (es) | 2008-10-20 | 2018-11-05 | Alnylam Pharmaceuticals Inc | Composiciones y metodos para inhibir la expresion de transtiretina. |
| EP2447274B1 (en) | 2008-10-24 | 2017-10-04 | Ionis Pharmaceuticals, Inc. | Oligomeric compounds and methods |
| CN111808084A (zh) | 2008-11-10 | 2020-10-23 | 阿布特斯生物制药公司 | 用于递送治疗剂的新型脂质和组合物 |
| SG10201911942UA (en) | 2009-05-05 | 2020-02-27 | Muthiah Manoharan | Lipid compositions |
| KR101766408B1 (ko) | 2009-06-10 | 2017-08-10 | 알닐람 파마슈티칼스 인코포레이티드 | 향상된 지질 조성물 |
| WO2011005980A1 (en) | 2009-07-09 | 2011-01-13 | Intradigm Corporation | Novel heterobifunctional polyethylene glycol reagents, their preparation and uses thereof |
| TWI458493B (zh) | 2009-09-25 | 2014-11-01 | Iner Aec Executive Yuan | 新穎肝標靶藥劑與合成方法 |
| TWI388338B (zh) | 2009-10-26 | 2013-03-11 | Iner Aec Executive Yuan | 對聚合醣鏈進行放射標誌以作為肝受體造影劑之方法 |
| TWI391144B (zh) | 2009-10-26 | 2013-04-01 | Iner Aec Executive Yuan | 一種定量肝殘餘功能的檢驗方法與其新穎肝受體造影檢驗藥劑 |
| WO2011072290A2 (en) | 2009-12-11 | 2011-06-16 | The Regents Of The University Of Michigan | Targeted dendrimer-drug conjugates |
| SI2539451T1 (sl) | 2010-02-24 | 2016-04-29 | Arrowhead Research Corporation | Sestavki za ciljano dostavo sirna |
| EP2553019A1 (en) | 2010-03-26 | 2013-02-06 | Mersana Therapeutics, Inc. | Modified polymers for delivery of polynucleotides, method of manufacture, and methods of use thereof |
| US20130236968A1 (en) | 2010-06-21 | 2013-09-12 | Alnylam Pharmaceuticals, Inc. | Multifunctional copolymers for nucleic acid delivery |
| CA2812046A1 (en) | 2010-09-15 | 2012-03-22 | Alnylam Pharmaceuticals, Inc. | Modified irna agents |
| WO2012068187A1 (en) | 2010-11-19 | 2012-05-24 | Merck Sharp & Dohme Corp. | Poly(amide) polymers for the delivery of oligonucleotides |
| US8501930B2 (en) | 2010-12-17 | 2013-08-06 | Arrowhead Madison Inc. | Peptide-based in vivo siRNA delivery system |
| AU2011343664B2 (en) * | 2010-12-17 | 2015-10-08 | Arrowhead Pharmaceuticals, Inc. | Galactose cluster-pharmacokinetic modulator targeting moiety for siRNA |
| CA3131967A1 (en) | 2010-12-29 | 2012-07-05 | F. Hoffman-La Roche Ag | Small molecule conjugates for intracellular delivery of nucleic acids |
| RS61447B1 (sr) | 2011-04-21 | 2021-03-31 | Glaxo Group Ltd | Modulacija ekspresije virusa hepatitisa b (hbv) |
| EA024762B9 (ru) * | 2011-06-30 | 2017-04-28 | Эрроухэд Рисерч Корпорейшн | Композиции и способы ингибирования экспрессии генов вируса гепатита в |
| WO2013032829A1 (en) | 2011-08-26 | 2013-03-07 | Arrowhead Research Corporation | Poly(vinyl ester) polymers for in vivo nucleic acid delivery |
| WO2013033230A1 (en) | 2011-08-29 | 2013-03-07 | Isis Pharmaceuticals, Inc. | Oligomer-conjugate complexes and their use |
| CA2842041A1 (en) * | 2012-04-18 | 2013-10-24 | Arrowhead Research Corporation | Poly(acrylate) polymers for in vivo nucleic acid delivery |
| US20150299696A1 (en) | 2012-05-02 | 2015-10-22 | Sirna Therapeutics, Inc. | SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS |
| AR090905A1 (es) | 2012-05-02 | 2014-12-17 | Merck Sharp & Dohme | Conjugados que contienen tetragalnac y peptidos y procedimientos para la administracion de oligonucleotidos, composicion farmaceutica |
| TW201808342A (zh) | 2012-05-02 | 2018-03-16 | 喜納製藥公司 | 包含四ｇａｌｎａｃ之新穎結合物及傳送寡核苷酸之方法 |
| US9150602B2 (en) | 2012-07-24 | 2015-10-06 | Atomic Energy Council, Institute Of Nuclear Energy Research | Precursor used for labeling hepatorcyte receptor and containing trisaccharide and diamide demercaptide ligand, method for preparing the same, radiotracer and pharmaceutical composition of the same |
| AU2013299717B2 (en) | 2012-08-06 | 2018-06-28 | Alnylam Pharmaceuticals, Inc. | Carbohydrate conjugated RNA agents and process for their preparation |
| CN104837996A (zh) | 2012-11-15 | 2015-08-12 | 罗氏创新中心哥本哈根有限公司 | 抗apob反义缀合物化合物 |
| AU2014211406B2 (en) | 2013-01-30 | 2019-07-18 | Roche Innovation Center Copenhagen A/S | LNA oligonucleotide carbohydrate conjugates |
| WO2014118272A1 (en) | 2013-01-30 | 2014-08-07 | Santaris Pharma A/S | Antimir-122 oligonucleotide carbohydrate conjugates |
| SG10201803157XA (en) | 2013-05-01 | 2018-05-30 | Regulus Therapeutics Inc | Microrna compounds and methods for modulating mir-122 |
| DK2992098T3 (da) | 2013-05-01 | 2019-06-17 | Ionis Pharmaceuticals Inc | Sammensætninger og fremgangsmåder til modulering af hbv- og ttr-ekspression |
| WO2015006740A2 (en) | 2013-07-11 | 2015-01-15 | Alnylam Pharmaceuticals, Inc. | Oligonucleotide-ligand conjugates and process for their preparation |
| EP3610884B1 (en) | 2013-11-06 | 2021-08-18 | Merck Sharp & Dohme Corp. | Peptide containing conjugates for dual molecular delivery of oligonucleotides |
| BR112016022742B1 (pt) | 2014-05-01 | 2022-06-14 | Ionis Pharmaceuticals, Inc | Composto químico, composição compreendendo o composto e uso dos mesmos |
| EP3151839A4 (en) | 2014-06-06 | 2018-02-28 | Ionis Pharmaceuticals, Inc. | Compositions and methods for enhanced intestinal absorption of conjugated oligomeric compounds |
| TW201620526A (zh) | 2014-06-17 | 2016-06-16 | 愛羅海德研究公司 | 用於抑制α－１抗胰蛋白酶基因表現之組合物及方法 |
| PL3164342T3 (pl) | 2014-07-01 | 2019-06-28 | Gima Tt S.P.A. | Opakowanie na wyroby do palenia |
| AU2015317958A1 (en) | 2014-09-15 | 2017-05-04 | Qubole, Inc. | Systems and methods for providing metadata-aware background caching in data analysis |
| CN106795200B (zh) | 2014-10-10 | 2020-06-19 | 豪夫迈·罗氏有限公司 | Galnac亚磷酰胺、其核酸缀合物及其用途 |
| CA2979703A1 (en) * | 2015-03-17 | 2016-09-22 | Arrowhead Pharmaceuticals, Inc. | Compositions and methods for inhibiting gene expression of factor xii |
| WO2016149020A1 (en) | 2015-03-17 | 2016-09-22 | Arrowhead Research Corporation | Rna interference agents |
| AU2016306275A1 (en) | 2015-08-07 | 2018-02-08 | Arrowhead Pharmaceuticals, Inc. | RNAi therapy for Hepatitis B virus infection |
| JOP20160211B1 (ar) * | 2015-10-01 | 2021-08-17 | Arrowhead Pharmaceuticals Inc | تراكيب وأساليب لتثبيط تعبير جيني للـ lpa |
| CA3011946A1 (en) | 2016-03-07 | 2017-09-14 | Arrowhead Pharmaceuticals, Inc. | Targeting ligands for therapeutic compounds |
| SG11201901841TA (en) | 2016-09-02 | 2019-03-28 | Arrowhead Pharmaceuticals Inc | Targeting ligands |
| CN110268060B (zh) * | 2017-01-10 | 2024-07-26 | 箭头药业股份有限公司 | α-1抗胰蛋白酶(AAT)RNAi物质、包含AAT RNAi物质的组合物和使用方法 |
| AU2018213379A1 (en) | 2017-01-30 | 2019-07-18 | Arrowhead Pharmaceuticals Inc. | Compositions and methods for inhibition of factor XII gene expression |
-
2017
- 2017-03-07 CA CA3011946A patent/CA3011946A1/en active Pending
- 2017-03-07 CN CN202110938247.8A patent/CN113797348A/zh active Pending
- 2017-03-07 MX MX2018009854A patent/MX2018009854A/es unknown
- 2017-03-07 KR KR1020237010168A patent/KR102830443B1/ko active Active
- 2017-03-07 KR KR1020227000160A patent/KR102515329B1/ko active Active
- 2017-03-07 EP EP17763911.9A patent/EP3426261A4/en active Pending
- 2017-03-07 TW TW106107454A patent/TWI727009B/zh active
- 2017-03-07 UY UY0001037146A patent/UY37146A/es active IP Right Grant
- 2017-03-07 AU AU2017229469A patent/AU2017229469B2/en active Active
- 2017-03-07 JO JOP/2017/0057A patent/JOP20170057B1/ar active
- 2017-03-07 US US15/452,423 patent/US10246709B2/en active Active
- 2017-03-07 TW TW111137872A patent/TWI842117B/zh active
- 2017-03-07 KR KR1020187027235A patent/KR102348425B1/ko active Active
- 2017-03-07 BR BR112018068230-6A patent/BR112018068230B1/pt active IP Right Grant
- 2017-03-07 JP JP2018547320A patent/JP6983797B2/ja active Active
- 2017-03-07 WO PCT/US2017/021175 patent/WO2017156012A1/en not_active Ceased
- 2017-03-07 CN CN201780016137.8A patent/CN109069529B/zh active Active
- 2017-03-07 IL IL296377A patent/IL296377A/en unknown
- 2017-03-07 TW TW110112971A patent/TWI783434B/zh active
-
2018
- 2018-08-14 MX MX2023006332A patent/MX2023006332A/es unknown
- 2018-08-14 MX MX2023006334A patent/MX2023006334A/es unknown
- 2018-09-04 IL IL261598A patent/IL261598B/en unknown
-
2019
- 2019-03-25 US US16/363,108 patent/US20190211333A1/en not_active Abandoned
-
2021
- 2021-02-24 US US17/184,575 patent/US12116573B2/en active Active
- 2021-08-19 JO JOP/2021/0231A patent/JOP20210231A1/ar unknown
- 2021-11-23 IL IL288341A patent/IL288341B2/en unknown
- 2021-11-24 JP JP2021189879A patent/JP7485642B2/ja active Active
-
2023
- 2023-05-17 AU AU2023203102A patent/AU2023203102B2/en active Active
-
2024
- 2024-05-02 JP JP2024074913A patent/JP2024097862A/ja not_active Withdrawn
- 2024-09-04 US US18/824,808 patent/US20250243485A1/en active Pending
-
2025
- 2025-06-03 JP JP2025092644A patent/JP2025120251A/ja active Pending
- 2025-08-06 AU AU2025213612A patent/AU2025213612A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019511491A5 (https=) | ||
| JP2012500197A5 (https=) | ||
| JP2014054250A5 (https=) | ||
| JP2011092201A5 (https=) | ||
| ES2537568T3 (es) | Nuevos fármacos para inhibición de la expresión genética | |
| JP2020531418A (ja) | 脂質ナノ粒子製剤における使用のための脂質 | |
| CY1119880T1 (el) | Παραγωγα πυρρολοπυριμιδινης για χρηση στη θεραπεια ιικων λοιμωξεων | |
| JP2018510621A5 (https=) | ||
| JP2018502956A5 (https=) | ||
| JP2018529732A5 (https=) | ||
| JP2017505623A5 (https=) | ||
| JP2018520685A5 (https=) | ||
| JP2012144574A5 (https=) | ||
| JP2012504133A5 (https=) | ||
| JP2014505704A5 (https=) | ||
| JP2006504658A5 (https=) | ||
| JP2017532982A (ja) | Ｓｍａｄ７アンチセンスオリゴヌクレオチドの同位体置換体 | |
| JP2008523098A5 (https=) | ||
| JP2019516739A5 (https=) | ||
| JP2017532038A5 (https=) | ||
| JP2014500861A5 (https=) | ||
| JP2015522264A5 (https=) | ||
| JP2014500230A5 (https=) | ||
| JP2023543898A5 (https=) | ||
| JP2017523790A5 (https=) |